STUDY OBJECTIVES: We compared @entity2400 with control, @entity3652 , @entity2898 prime, and large-dose @entity2898 (0.9 mg/kg) with regard to intubation conditions during rapid-sequence induction. DESIGN: This is a prospective, randomized, double-blinded study. SETTING: The setting is at an operating room in a university-affiliated hospital. @entity1 : One hundred ten @entity1 scheduled for general anesthesia were randomly allocated to the following 5 groups in equal numbers. INTERVENTIONS: The control and @entity2898 0.9 groups received @entity2898 0.6 and 0.9 mg/kg, respectively; the @entity3652 group was given 0.5 mg/kg @entity3652 2 minutes before 0.6 mg/kg @entity2898 ; the @entity2898 prime group received 0.06 mg/kg @entity2898 3 minutes before 0.54 mg/kg @entity2898 ; and the @entity1760 group received 50 mg/kg @entity2400 . Intubation was initiated 50 seconds after the @entity2898 injection. MEASUREMENTS: Intubating condition (primary outcome), @entity2898 onset, @entity2898 duration, train-of-four ratio upon intubation, and hemodynamic variables (secondary outcomes) were recorded. MAIN RESULTS: The excellent intubating condition was more frequent in the @entity1760 group (P < .05). Onset of @entity4094 was shorter in the @entity1760 group than in the control, @entity3652 , and @entity2898 prime groups (P < .05). No difference in onset time was found between the @entity1760 and @entity2898 0.9 groups. Block duration was longest in the @entity2898 0.9 group. The train-of-four ratio on intubation was lowest in the @entity2898 prime group. The only adverse event was a @entity809 reported by 5 @entity1 in the @entity1760 group. CONCLUSIONS: @entity2400 pretreatment was most likely to provide excellent intubating condition for rapid-sequence intubation compared with the control, @entity3652 pretreatment, @entity2898 prime, and large-dose @entity2898 . However, @entity2400 administration is associated with a @entity809 .

The effect of XXXX on intubating condition for rapid-sequence intubation: a randomized controlled trial.

@entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS'] @entity4094 :: ('MESH:D009468', 'Disease') :: ['neuromuscular block'] @entity809 :: ('MESH:D010292', 'Disease') :: ['burning or heat sensation'] @entity3652 :: ('MESH:D007649', 'Chemical') :: ['ketamine'] @entity2400 :: ('CHEBI:32599', 'Chemical') :: ['magnesium sulphate', 'Magnesium sulphate'] @entity2898 :: ('MESH:C061870', 'Chemical') :: ['rocuronium'] @entity1760 :: ('MESH:D008274', 'Chemical') :: ['magnesium']
@entity2400 :: (CHEBI:32599,Chemical) :: ['magnesium sulphate']
